Balchem Corporation 10-K Summary (Fiscal Year Ended Dec 31, 2003)
Business Context and Reporting Period
Balchem Corporation (Balchem) is a developer, manufacturer, and marketer of specialty performance ingredients for the food, feed, and medical sterilization industries. The company operates through three segments: Specialty Products (ethylene oxide, propylene oxide, methyl chloride), Encapsulated/Nutritional Products (microencapsulation for food and animal health), and BCP Ingredients (choline chloride for animal feed). This report covers the fiscal year ended December 31, 2003.
Key Financial Metrics
| Metric | 2003 | 2002 |
|---|---|---|
| Net Sales | $61,875,000 | $60,197,000 |
| Gross Profit | $21,152,000 | $23,310,000 |
| Gross Margin | 34.2% | 38.7% |
| Net Earnings | $5,638,000 | $7,416,000 |
| Diluted EPS | $1.13 | $1.50 |
| Operating Cash Flow | $11,153,000 | $10,114,000 |
| Capital Expenditures | $2,270,000 | $10,020,000 |
| Long-Term Debt | $7,839,000 | $9,581,000 |
| Cash and Equivalents | $9,239,000 | $1,731,000 |
| Working Capital | $17,555,000 | $10,884,000 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 2.8% to $61.9 million. Specialty Products sales rose 18.8% due to higher ethylene oxide volumes and new single-use canister business. BCP Ingredients sales grew 14.6% on increased choline chloride volumes.
- Segment Decline: Encapsulated/Nutritional Products sales fell 14.1% to $24.0 million. This was driven by the absence of a $2.2 million one-time sale to a single customer in 2002, slower market acceptance of new food products, and unfavorable product mix.
- Profitability: Net earnings declined 24% to $5.6 million. The Encapsulated/Nutritional segment reported a loss of $962,000 compared to $5.1 million in earnings the prior year, largely due to excess manufacturing capacity and lower volumes. Specialty Products earnings increased to $9.4 million.
- Liquidity: Cash and cash equivalents surged to $9.2 million (from $1.7 million) due to strong operating cash flow and a strategic reduction in inventory levels.
Outlook, Risks, and Management Commentary
- Outlook: Management projects capital expenditures of approximately $1.7 million for 2004. The company expects operations to generate sufficient cash flow to fund working capital and debt obligations.
- Regulatory Risk: The company's ability to sell ethylene oxide depends on EPA re-registration. While testing is complete, the EPA has not set a completion date due to a backlog. Management believes re-registration will be successful as the product has no known substitute.
- Customer Concentration: One customer (Sterigenics) accounted for 10% of net sales and 12% of accounts receivable in 2003. Loss of this customer could have a material adverse effect.
- Environmental: The Verona, Missouri facility was a Superfund site due to prior dioxin contamination. Remediation is believed complete, and the company is indemnified by the prior owner for future liabilities.
- Unusual Items: Operating expenses included a $400,000 charge for organizational changes in the Encapsulated/Nutritional segment. Increased medical claims and insurance premiums negatively impacted margins across all segments.
Investor Verification Checklist
- EPA Re-registration Status: Verify the timeline for the EPA's decision on ethylene oxide re-registration, as this is critical to the Specialty Products segment.
- Encapsulated Segment Turnaround: Monitor the performance of the Encapsulated/Nutritional segment to see if it returns to profitability following the loss in 2003.
- Customer Concentration: Assess the stability of the relationship with Sterigenics (10% of sales) and the risk of customer consolidation in the sterilization industry.
- Debt Covenants: Confirm continued compliance with the Loan Agreement covenants, specifically financial ratios, given the decline in earnings.
- Inventory Levels: Review if the strategic inventory reduction in the Encapsulated segment impacts future ability to meet demand or if it was a permanent shift.